Posted On: 07/14/2016 11:03:57 AM
Post# of 72436
$30 mil is the cost of B-ABSSSI Phase 3 trials (that's what Dr Bertolino said in the interview). $30 mil is the end game that will lead to NDA of B-ABSSSI.
Yes, they don't need to pay the whole lump sum of that $30 mil upfront to the CRO
Leo can raise money as it goes .
But why would he want to risk such a pivotal trial by not having the money fully secured for the trial since he already know the budget?
Aspire may not necessarily want to do a deal with CTIX if poor financial market circumstances arises.
Even NNVC has about $40 mil in the bank when they uplisted to AMEX 2 years ago and they don't even have any clinical trials conducted!
Yes, they don't need to pay the whole lump sum of that $30 mil upfront to the CRO
Leo can raise money as it goes .
But why would he want to risk such a pivotal trial by not having the money fully secured for the trial since he already know the budget?
Aspire may not necessarily want to do a deal with CTIX if poor financial market circumstances arises.
Even NNVC has about $40 mil in the bank when they uplisted to AMEX 2 years ago and they don't even have any clinical trials conducted!
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)